HCF P&T Committee
The Pharmacy and Therapeutics (P&T) Committee
The P&T Committee provides recommendations for the Medicaid Preferred Drug List (PDL). The Committee is composed of Physicians & Pharmacists who meet at least quarterly to consider PDL implementation. These meetings are generally scheduled on the third Thursday of every month at 7:00 A.M. in the Cannon Health Building at 288 N. 1460 W. in Salt Lake City, UT. The P&T Committee reserves the right to adjust the meeting schedule as necessary. Notices for exact meeting times and locations will be published in the Legal Notices sections of the Salt Lake Newspapers at least 24 hours in advance.
The meetings are open to the public. To receive public notice for this meeting by email please sign up on the Utah Public Notice website.
Public Comments for the P&T Committee:
Public comment that responds to the materials presented by the Pharmacotherapy Outcomes Research Center at the Universityof Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-Based Practice Center or the Pharmacotherapy Outcomes Research Center and are posted in advance on the P&T Committee website
Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:
Gary M. Oderda, Pharm.D., M.P.H
Professor and Director
Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
421 Wakara Way Suite 208
Salt Lake City, UT 84108
All materials must be clearly labeled that they are submitted for consideration as part of the State of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Persons who wish to address the P&T Committee may contact Lisa Hunt by phone at 801-538-6317 or by email at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints
Listed below is a P&T Committee class review tentative schedule:
|P&T Tentative Schedule
|2/20/2014||Short Acting Opioid Agents||Codeine products, tramadol products, hydrocodone products, hydromorphone, Levorphanol, Meperidine, Tapentadol IR, Paregoric
||Antiemetics||Droperidol, Hydroxyzine, Meclizine, Nabilone, Prochlorperazine, Promethazine, Trimethobenzamide, Metoclopramide (Prokinetic Agent)
|Appetite Stimulants||Dronabinol, Megestrol
|Epipen Formulations||Adrenaclick, Auvi-Q, EpiPen Jr, Epinephrine
||Antihistamines 1st Generation Agents||Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Dexchlorpheniramine, Dimenhydrinate,Diphenhydramine, Doxylamine, Hydroxyzine (including all combination agents)
|Antihistamines 2nd Generation Agents||Cetirizine, Desloratadine, Fexofenadine, Ketotifen, Levocetirizine, Loratadine
(including all combination agents)
Listed below are meeting minutes, recordings, agendas, criteria review documents, and reports regarding the P&T Committee. Clinical evidence documents prepared for the P&T Committee meetings will be kept on this website for 6 months.
Meeting recordings will be available online for 1 year. For historical meeting recordings please contact us at email@example.com.
Search the following files. Note that '*' and '?' wildcards are supported.
Parent Directory|| || |
January 21, 2014
February 21, 2013
February 26, 2014
March 21, 2013
April 23, 2013
May 16, 2013
July 19, 2013
August 15, 2013
September 19, 2013
November 21, 2013
January 30, 2014